TB-403 — Investigational Agent
Monoclonal Antibody · Phase 1/2 · Oncurious / Mireca Medicines
Mechanism of Action
Humanized monoclonal antibody targeting placental growth factor (PlGF), disrupting PlGF/neuropilin and VEGFR-1 signaling implicated in medulloblastoma growth and angiogenesis. Blockade aims to inhibit tumor proliferation and vascular support in PlGF-dependent tumors.
Investigational Indications
- Relapsed/refractory medulloblastoma
- Pediatric solid tumors